Intezyne Technologies
Intezyne Technologies: Advancing cancer treatment through innovative biomedical research and synthetic polymers.
Founded
2004Intezyne Technologies: Advancing cancer treatment through innovative biomedical research and synthetic polymers.
Intezyne Technologies, founded with a mission to revolutionize cancer treatment, focuses on advancing biomedical research through the development of synthetic polymers for drug delivery. The company's vision is to create breakthrough therapies that significantly improve patient outcomes in cancer care. Intezyne's core products and services revolve around innovative drug delivery systems designed to enhance the efficacy and safety of cancer treatments, targeting a market that demands more effective and less toxic therapeutic options.
Notable affiliated individuals and investors include experts in oncology and biomedical research, although specific names are not publicly highlighted. Intezyne Technologies has achieved significant milestones in preclinical and clinical trials, demonstrating the potential of their polymer-based delivery systems to improve drug performance. The overall impact of Intezyne's work is seen in its contributions to more effective cancer therapies, offering hope for better patient experiences and outcomes in the fight against cancer.
Companies similar to Intezyne Technologies include ZY Therapeutics, Syntis Bio, Intact Therapeutics and Zymeron.
Intezyne Technologies was founded in 2004.
Intezyne Technologies' headquarters is located in Tampa, FL, US.
Intezyne Technologies' most recent funding round was for $10M (USD) in October 2017.
As of Oct 6, 2017, Intezyne Technologies has raised a total of $10.5M (USD).
Intezyne Technologies has 15 employees as of Feb 5, 2024.
Intact Therapeutics
